Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Vaccines

Free Subscription 11.02.2019 2 Arch Virol 2 BMC Pediatr 1 BMJ 3 Clin Infect Dis 13 J Infect Dis 1 J Virol 2 Lancet 6 Lancet Infect Dis 1 MMWR Morb Mortal Wkly Rep 4 PLoS One 1 Science 19 Vaccine

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Arch Virol

1. EVSEENKO VA, Kolosova NP, Gudymo AS, Maltsev SV, et al
   Intranasal immunization of guinea pig with trivalent influenza antigen adjuvanted by Cyclamen europaeum tubers extract.
   Arch Virol. 2018 Sep 17. pii: 10.1007/s00705-018-4023.
   PubMed     Text format     Abstract available
   
   
2. MULLER C, Ulrich R, Franzke K, Muller M, et al
   Crude extracts of recombinant baculovirus expressing rabbit hemorrhagic disease virus 2 VLPs from both insect and rabbit cells protect rabbits from rabbit hemorrhagic disease caused by RHDV2.
   Arch Virol. 2019;164:137-148.
   PubMed     Text format     Abstract available
   
   

   
   BMC Pediatr

3. FAUST SN, Le Roy M, Pancharoen C, Weber MAR, et al
   Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.
   BMC Pediatr. 2019;19:50.
   PubMed     Text format     Abstract available
   
   
4. CARVALHO-COSTA FA, de Assis RMS, Fialho AM, Araujo IT, et al
   The evolving epidemiology of rotavirus A infection in Brazil a decade after the introduction of universal vaccination with Rotarix(R).
   BMC Pediatr. 2019;19:42.
   PubMed     Text format     Abstract available
   
   

   
   BMJ

5. DYER O
   Cervical cancer: deaths increase as HPV vaccine is underused, says WHO.
   BMJ. 2019;364:l580.
   PubMed     Text format    
   
   

   
   Clin Infect Dis

6. KOREM M, Orenbuch-Harroch E, Ben-Chetrit E, Israel S, et al
   Intensive care admissions and associated severity of influenza B versus A during influenza B-vaccine mismatched seasons.
   Clin Infect Dis. 2019 Feb 1. pii: 5305596. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
7. ROLFES MA, Flannery B, Chung J, O'Halloran A, et al
   Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season.
   Clin Infect Dis. 2019 Feb 2. pii: 5305915. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
8. NEUZIL KM, Fitzpatrick MC
   The Impact of Influenza Vaccine: It's the Size of the Glass.
   Clin Infect Dis. 2019 Feb 2. pii: 5306034. doi: 10.1093.
   PubMed     Text format    
   
   

   
   J Infect Dis

9. ROSS TM
   Universal Influenza Vaccine Approaches Employing Full-Length or Head-only HA Proteins.
   J Infect Dis. 2019 Jan 31. pii: 5304925. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
10. RUDRARAJU R, Mordant F, Subbarao K
    How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
    J Infect Dis. 2019 Jan 31. pii: 5304927. doi: 10.1093.
    PubMed     Text format    
    
    
11. CRANK MC, Mascola JR, Graham BS
    Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.
    J Infect Dis. 2019 Jan 31. pii: 5304928. doi: 10.1093.
    PubMed     Text format    
    
    
12. FOLSCHWEILLER N, Behre U, Dionne M, Durando P, et al
    Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
    J Infect Dis. 2019 Feb 3. pii: 5306135. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
13. SAAD-ROY CM, McDermott AB, Grenfell BT
    Dynamic perspectives on the search for a universal influenza vaccine.
    J Infect Dis. 2019 Jan 31. pii: 5304934. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
14. PAULES CI, Fauci AS
    Influenza Vaccines: Good, But We Can Do Better.
    J Infect Dis. 2019 Jan 31. pii: 5304932. doi: 10.1093.
    PubMed     Text format    
    
    
15. ZELNER J, Petrie JG, Trangucci R, Martin ET, et al
    Effects of sequential influenza A(H1N1)pdm09 vaccination on antibody waning.
    J Infect Dis. 2019 Feb 4. pii: 5306487. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
16. KANEKIYO M, Ellis D, King NP
    New Vaccine Design and Delivery Technologies.
    J Infect Dis. 2019 Jan 31. pii: 5304933. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
17. ORTIZ JR, Neuzil KM
    Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines.
    J Infect Dis. 2019 Jan 31. pii: 5304930. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
18. MORENS DM, Taubenberger JK
    Making Universal Influenza Vaccines: Lessons from the 1918 Pandemic.
    J Infect Dis. 2019 Jan 31. pii: 5304851. doi: 10.1093.
    PubMed     Text format    
    
    
19. KRAMMER F, Palese P
    Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain.
    J Infect Dis. 2019 Jan 31. pii: 5304926. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
20. EICHELBERGER MC, Monto AS
    Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection.
    J Infect Dis. 2019 Jan 31. pii: 5304892. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
21. SAELENS X
    The Role of M2e in the Development of Universal Influenza Vaccines.
    J Infect Dis. 2019 Jan 31. pii: 5304896. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Virol

22. WU Q, Rivailler P, Xu S, Xu W, et al
    Comparison of the whole genome sequence of an Oka varicella vaccine from China with other Oka vaccine strains reveals sites putatively critical for vaccine efficacy.
    J Virol. 2019 Feb 6. pii: JVI.02281-18. doi: 10.1128/JVI.02281.
    PubMed     Text format     Abstract available
    
    

    
    Lancet

23. THE LANCET
    Cervical cancer: unequal progress.
    Lancet. 2019;393:104.
    PubMed     Text format    
    
    
24. COHEN PA, Jhingran A, Oaknin A, Denny L, et al
    Cervical cancer.
    Lancet. 2019;393:169-182.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Infect Dis

25. VEKEMANS J, Gebreselassie N, Zignol M, Friede M, et al
    A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration.
    Lancet Infect Dis. 2019;19:123-125.
    PubMed     Text format    
    
    
26. LECHNER M, Jones OS, Breeze CE, Gilson R, et al
    Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness.
    Lancet Infect Dis. 2019;19:131-132.
    PubMed     Text format    
    
    
27. SACK DA
    Enhancing immune responses to oral vaccines: still an enigma.
    Lancet Infect Dis. 2019;19:122-123.
    PubMed     Text format    
    
    
28. CHURCH JA, Parker EP, Kirkpatrick BD, Grassly NC, et al
    Interventions to improve oral vaccine performance: a systematic review and meta-analysis.
    Lancet Infect Dis. 2019;19:203-214.
    PubMed     Text format     Abstract available
    
    
29. RODRIGUEZ-BARRAQUER I, Salje H, Cummings DA
    Dengue pre-vaccination screening and positive predictive values.
    Lancet Infect Dis. 2019;19:132-134.
    PubMed     Text format    
    
    
30. FERREIRA LLG, Andricopulo AD
    Drugs and vaccines in the 21st century for neglected diseases.
    Lancet Infect Dis. 2019;19:125-127.
    PubMed     Text format    
    
    

    
    MMWR Morb Mortal Wkly Rep

31. BAURI M, Wilkinson AL, Ropa B, Feldon K, et al
    Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 1 and Outbreak Response - Papua New Guinea, 2018.
    MMWR Morb Mortal Wkly Rep. 2019;68:119-120.
    PubMed     Text format    
    
    

    
    PLoS One

32. MARTINEZ L, Milanic M, Malaina I, Alvarez C, et al
    Weighted lambda superstrings applied to vaccine design.
    PLoS One. 2019;14:e0211714.
    PubMed     Text format     Abstract available
    
    
33. KIM HW, Lee HY, Kim SE, Ahn HY, et al
    Perceptions of nurses on human papillomavirus vaccinations in the Republic of Korea.
    PLoS One. 2019;14:e0211475.
    PubMed     Text format     Abstract available
    
    
34. LEVY C, Varon E, Ouldali N, Wollner A, et al
    Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine.
    PLoS One. 2019;14:e0211712.
    PubMed     Text format     Abstract available
    
    
35. ACHARYA P, Kismul H, Mapatano MA, Hatloy A, et al
    Individual- and community-level determinants of child immunization in the Democratic Republic of Congo: A multilevel analysis.
    PLoS One. 2018;13:e0202742.
    PubMed     Text format     Abstract available
    
    

    
    Science

36. WILSON JT
    A sweeter approach to vaccine design.
    Science. 2019;363:584-585.
    PubMed     Text format    
    
    

    
    Vaccine

37. ADDISON M, Lazzaro T, Crawford N
    Injection site abscess (ISA) following an infant vaccine.
    Vaccine. 2019 Jan 28. pii: S0264-410X(19)30079.
    PubMed     Text format    
    
    
38. AMADOR-MOLINA A, Trejo-Moreno C, Romero-Rodriguez D, Sada-Ovalle I, et al
    Vaccination with human papillomavirus-18 E1 protein plus alpha-galactosyl-ceramide induces CD8(+) cytotoxic response and impairs the growth of E1-expressing tumors.
    Vaccine. 2019 Jan 28. pii: S0264-410X(18)31709.
    PubMed     Text format     Abstract available
    
    
39. QUINN SC, Jamison AM, An J, Hancock GR, et al
    Measuring vaccine hesitancy, confidence, trust and flu vaccine uptake: Results of a national survey of White and African American adults.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30096.
    PubMed     Text format     Abstract available
    
    
40. SHAPIRO JR, Hodgins B, Hendin HE, Patel A, et al
    Needle-free delivery of influenza vaccine using the Med-Jet(R) H4 is efficient and elicits the same humoral and cellular responses as standard IM injection: A randomized trial.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30103.
    PubMed     Text format     Abstract available
    
    
41. MOTTRAM L, Chakraborty S, Cox E, Fleckenstein J, et al
    How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30069.
    PubMed     Text format     Abstract available
    
    
42. XU S, Newcomer SR, Kulldorff M, Daley MF, et al
    Use of three summary measures of pediatric vaccination for studying the safety of the childhood immunization schedule.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30104.
    PubMed     Text format     Abstract available
    
    
43. PADMANABHA N, Kini JR, Alwani AA, Sardesai A, et al
    Acceptability of human papillomavirus vaccination among medical students in Mangalore, India.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30095.
    PubMed     Text format     Abstract available
    
    
44. BORRAS E, Urbiztondo L, Carmona G, Jane M, et al
    Effectiveness and impact of the hepatitis B vaccination program in preadolescents in Catalonia 21 years after its introduction.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30078.
    PubMed     Text format     Abstract available
    
    
45. MONTESINO R, Gutierrez N, Camacho F, Farnos O, et al
    Multi-antigenic recombinant subunit vaccine against Lawsonia intracellularis: The etiological agent of porcine proliferative enteropathy.
    Vaccine. 2019 Jan 30. pii: S0264-410X(19)30092.
    PubMed     Text format     Abstract available
    
    
46. ROY S, Jaeson MI, Li Z, Mahboob S, et al
    Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes.
    Vaccine. 2019 Feb 4. pii: S0264-410X(19)30121.
    PubMed     Text format     Abstract available
    
    
47. STASI C, Monnini M, Cellesi V, Salvadori M, et al
    Screening for hepatitis B virus and accelerated vaccination schedule in prison: A pilot multicenter study.
    Vaccine. 2019 Feb 4. pii: S0264-410X(19)30125.
    PubMed     Text format     Abstract available
    
    
48. SHEIKH S, Biundo E, Courcier S, Damm O, et al
    Corrigendum to 'A report on the status of vaccination in Europe' [Vaccine 36 (2018) 4979-4992].
    Vaccine. 2019 Feb 4. pii: S0264-410X(19)30102.
    PubMed     Text format    
    
    
49. NOLAN MB, Schulman ML, Botha AE, Human AM, et al
    Serum antibody immunoreactivity and safety of native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant in horses.
    Vaccine. 2019 Feb 4. pii: S0264-410X(19)30129.
    PubMed     Text format     Abstract available
    
    
50. DEMPSEY AF, Pyrzanowski J, Campagna EJ, Lockhart S, et al
    Parent report of provider HPV vaccine communication strategies used during a randomized, controlled trial of a provider communication intervention.
    Vaccine. 2019 Feb 4. pii: S0264-410X(19)30127.
    PubMed     Text format     Abstract available
    
    
51. RAO S, Alishahi M, De Crescenzo L, Dempsey AF, et al
    A population-based study of maternal and infant factors influencing influenza vaccination among young children born in Colorado from 2008 to 2016.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30130.
    PubMed     Text format     Abstract available
    
    
52. ABENTE EJ, Rajao DS, Gauger PC, Vincent AL, et al
    Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30052.
    PubMed     Text format     Abstract available
    
    
53. BEARSON SMD, Bearson BL, Sylte MJ, Looft T, et al
    Cross-protective Salmonella vaccine reduces cecal and splenic colonization of multidrug-resistant Salmonella enterica serovar Heidelberg.
    Vaccine. 2019 Feb 1. pii: S0264-410X(19)30027.
    PubMed     Text format     Abstract available
    
    
54. KIM T, Hong JK, Oem JK, Lee KN, et al
    Cross-protective efficacy of the O1 Manisa+O 3039 bivalent vaccine and the O 3039 monovalent vaccine against heterologous challenge with FMDV O/Jincheon/SKR/2014 in pig.
    Vaccine. 2019 Jan 31. pii: S0264-410X(18)31644.
    PubMed     Text format     Abstract available
    
    
55. MARECHAL C, Lal H, Poder A, Ferguson M, et al
    Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults >/=50years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].
    Vaccine. 2019 Jan 30. pii: S0264-410X(19)30076.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: